$1.7 Million Settlement – Medical Malpractice

Seeger Weiss Obtains $1.7 Million Recovery for Physician’s Failure to Diagnose Renal Disease in Timely Manner In a medical malpractice case pending in Supreme Court, Bronx County, Seeger Weiss came to a $1.7 million settlement agreement earlier this month on behalf of a client who has been diagnosed with end stage renal disease. The case, […]

August 9, 2010

Medical Malpractice

Seeger Weiss Obtains $1.7 Million Recovery for Physician’s Failure to Diagnose Renal Disease in Timely Manner

In a medical malpractice case pending in Supreme Court, Bronx County, Seeger Weiss came to a $1.7 million settlement agreement earlier this month on behalf of a client who has been diagnosed with end stage renal disease.

The case, brought against our client’s primary care physician, alleged that the physician’s failed to recognize signs and symptoms of kidney dysfunction over a period of nearly two years. In addition, this failure to diagnose and treat the client’s condition in its early stages was a significant factor in our client’s current diagnosis of advanced renal disease.

“This case underscores the importance of closely monitoring even routine blood test results,” said Seeger Weiss partner Marc S. Albert. “Simply put, this client’s kidney disease should have been diagnosed much earlier than it ultimately was. Unfortunately, blood tests over nearly a two year period, which showed elevated and continuously rising Creatinine and BUN levels—clear indications of renal disease—were not being carefully reviewed by his physician.”

During the course of the case, our client appeared on a CBS News special highlighting a problem that has become somewhat endemic in the medical field: physicians’ cavalier approach to reviewing patient’s test results. CBS, in a recent news story, reported on a number of patients—including our client—who had serious medical conditions slip through the cracks when test results were not carefully evaluated by their physician.

“We are extremely satisfied with what we feel is a just result for our client in this case,” said Mr. Albert.

Notwithstanding claims relating to this product, the drug/medical device remains approved by the U.S. FDA.

Related News

June 12, 2025
Seeger Weiss and Partners Recognized in the Chambers 2025 USA Guide

Seeger Weiss is proud to announce that the firm—alongside partners Christopher Seeger, David Buchanan, Ben Barnett, and Parvin Aminolroaya—has been recognized in the newly released Chambers 2025 USA Guide. This marks the fifth consecutive year that Seeger Weiss has been recognized by Chambers USA. For over three decades, Chambers has been a trusted authority in […]

Read More
June 10, 2025
Ten Seeger Weiss Attorneys Named to Lawdragon’s 2025 500 Leading Plaintiff Financial Lawyers List

We are proud to announce that ten Seeger Weiss attorneys have been selected to Lawdragon’s 2025 Leading Plaintiff Financial Lawyers guide list, which honors attorneys who represent plaintiffs in complex financial litigation. Congratulations to Parvin Aminolroaya, Christopher Ayers, Ben Barnett, David R. Buchanan, Steven Daroci, Shauna Itri, Jeremy Kasha, Jennifer Scullion, Christopher Seeger, and Stephen […]

Read More
May 28, 2025
Seeger Weiss Establishes Fund at Bolch Judicial Institute to Defend the Judiciary and Honor Daniel Anderl

Seeger Weiss LLP, led by founding partner Christopher A. Seeger, has made a $500,000 donation to the Bolch Judicial Institute at Duke Law School to establish The Seeger Weiss/Daniel Anderl Memorial Fund, which will provide long-term, flexible funding for the Institute to support two critical areas of the legal system: defending judicial independence and advancing […]

Read More